抗肿瘤多药耐药微管蛋白调节剂的研究进展
投稿时间:2017-05-03  修订日期:2017-06-19  点此下载全文
引用本文:施赛健,张文,厉廷有,庄春林.抗肿瘤多药耐药微管蛋白调节剂的研究进展[J].药学实践杂志,2017,35(5):385~393,397
摘要点击次数: 1217
全文下载次数: 3333
作者单位E-mail
施赛健 南京医科大学药学院药物化学系, 江苏 南京 211166  
张文 第二军医大学药学院海洋药物研究中心, 上海 200433  
厉廷有 南京医科大学药学院药物化学系, 江苏 南京 211166  
庄春林 第二军医大学药学院海洋药物研究中心, 上海 200433 zclnathan@163.com 
基金项目:上海市教委青年科研骨干培养计划(晨光计划,16CG42)
中文摘要:2015年,全世界有超过800万人死于肿瘤。传统化疗药物仍广泛应用于临床一线,但超过50%的肿瘤对此类药物产生明显的耐药性。微管蛋白调节剂已成为临床证实有效的抗癌药物。然而,紫杉醇、长春碱等传统微管蛋白调节剂也会产生严重耐药。近年来,研究发现作用于微管蛋白秋水仙碱位点的微管蛋白调节剂对抗肿瘤多药耐药具有很好的效果。本文综述近年来此类抗肿瘤多药耐药微管蛋白调节剂的研究进展。
中文关键词:抗肿瘤  多药耐药  微管蛋白  调节剂
 
Recent research progress on anti-microtubule agents targeting multi-drug resistant cancers
Abstract:In 2015, more than 8 million people died from various kinds of cancers all over the world. Although traditional chemotherapeutic drugs are widely used in clinic, more than 50% of cancers are significantly resistant to traditional chemotherapeutic drugs. Tubulin targeting agents have been confirmed to be effective anti-cancer drugs in clinic. However, some anti-microtubule agents developed resistance after long-term use, such as paclitaxel and vinblastine. In recent years, it is reported that tubulin modulators targeting on the colchicine-binding site are extremely effective against multi-drug resistant cancer cells. In this article, different anti-microtubule agents targeting multi-drug resistant cancers are reviewed.
keywords:anti-cancer  multidrug resistant  tubulin  modulator
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮